Skip to content
Bored Studies
RecruitingPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Eli Lilly and Company · NCT06857942

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 4
Target enrollment
200
US sites recruiting
39
Study start
March 19, 2025
Record last updated
September 4, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity.

The study will last up to 12 months.

Being studied: Tirzepatide

Conditions: Psoriasis; Overweight or Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant)
  • Have body mass index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m² to \<30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular diseases).
  • Must have initiated treatment with ixekizumab for approximately 3 months (± 1 month) prior to decision to add tirzepatide.
  • Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline/screening).

Exclusion Criteria

  • Have currently received ixekizumab for more than 4 months or less than 2 months.
  • Have had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide.
  • Are currently enrolled in any other clinical study.

Other exclusions

  • Have a known hypersensitivity to tirzepatide or to any of its component.
  • Have a personal or family history of medullary thyroid cancer.
  • Have multiple endocrine neoplasia type 2.
  • Have type I diabetes mellitus.
  • Have a history of chronic or acute pancreatitis at any time before screening (Visit 1).
  • Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment.
  • Have a history of ketoacidosis or hyperosmolar state/coma.
  • Have a history of severe hypoglycemia and hypoglycemia unawareness within the 6 months before screening.
  • Have a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/constipation/vomiting.

Recruiting US locations

  • Medical Dermatology Specialists

    Phoenix, AZ 85006

    Site contact: 602-354-5770

  • First OC Dermatology Research Inc

    Fountain Valley, CA 92708

    Site contact: 714-531-2966

  • Center For Dermatology Clinical Research, Inc.

    Fremont, CA 94538

    Site contact: 510-797-0140

  • Metropolis Dermatology

    Los Angeles, CA 90017

    Site contact: 424-393-0005

  • Northridge Clinical Trials

    Northridge, CA 91325

    Site contact: 818-350-7482

  • NeoClinical Research

    Hialeah, FL 33016

    Site contact: 305-456-9062

  • Skin Care Research

    Hollywood, FL 33021

    Site contact: 954-674-3535

  • Encore Medical Research

    Hollywood, FL 33024

    Site contact: 954-400-1725

  • MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research

    Tampa, FL 33607

    Site contact: 813-948-7550

  • TruDerm & TruSpa

    Wellington, FL 33449

    Site contact: Andleeb Usmani

  • Southeast Research Specialists

    Douglasville, GA 30135

    Site contact: 678-702-3376

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, IN 46250

    Site contact: 317-516-5030

  • The Indiana Clinical Trials Center, PC

    Plainfield, IN 46168

    Site contact: 317-837-6082

  • Equity Medical - Bowling Green

    Bowling Green, KY 42104

    Site contact: 270-213-7777

  • Dermatology and Skin Cancer Specialists, LLC

    Rockville, MD 20850

    Site contact: Benjamin Lockshin

  • Metro Boston Clinical Partners

    Brighton, MA 02135

    Site contact: Mark Amster

  • David Fivenson, MD, PLC

    Ann Arbor, MI 48103

    Site contact: 734-222-9630

  • The Derm Institute of West Michigan

    Caledonia, MI 49316

    Site contact: 616-326-0114

  • Skin Cancer and Dermatology Institute - Reno

    Reno, NV 89509

    Site contact: 775-336-3658

  • Stracskin

    Portsmouth, NH 03801

    Site contact: 617-833-9995

  • Psoriasis Treatment Center of Central New Jersey

    East Windsor, NJ 08520

    Site contact: Alexa Hetzel

  • Care Access - Hoboken

    Hoboken, NJ 07030

    Site contact: 551-278-8680

  • Equity Medical

    New York, NY 10023

    Site contact: 212-466-6550

  • Revival Research Institute, LLC

    Cary, NC 27511

    Site contact: Zain Husain

  • Onsite Clinical Solutions - Huntersville

    Huntersville, NC 28078

    Site contact: 800-785-3150

  • Optima Research - Boardman

    Boardman, OH 44512

    Site contact: 330-422-3234

  • Oregon Dermatology and Research Center

    Portland, OR 97210

    Site contact: 503-226-3376

  • Dermatology Associates of Plymouth Meeting

    Plymouth Meeting, PA 19462

    Site contact: Jonathan Wolfe

  • Columbia Dermatology & Aesthetics

    Columbia, SC 29212

    Site contact: 803-731-9600

  • DelRicht Research - Thompson's Station

    Smyrna, TN 37167

    Site contact: 629-895-1775

  • Bellaire Dermatology Associates

    Bellaire, TX 77401

    Site contact: 713-661-4383

  • Modern Research Associates, PLLC

    Dallas, TX 75231

    Site contact: 214-361-2008

  • Center for Clinical Studies

    Houston, TX 77004

    Site contact: 713-528-8818

  • Austin Institute for Clinical Research

    Pflugerville, TX 78660

    Site contact: 512-279-2545

  • Texas Dermatology and Laser Specialists

    San Antonio, TX 78218

    Site contact: 210-852-2779

  • Center for Clinical Studies

    Webster, TX 77598

    Site contact: 281-333-2288

  • Tanner Clinic

    Layton, UT 84041

    Site contact: Scott Checketts

  • Bellevue Dermatology Clinic

    Bellevue, WA 98104

    Site contact: 425-455-2275

  • Dermatology of Seattle

    Burien, WA 98168

    Site contact: 206-248-5020

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All weight loss studies in Arizona →
A Study to Investigate the Effectiveness of Tirzepatide… (NCT06857942) | Bored Studies